Welcome to our dedicated page for Sohm news (Ticker: SHMN), a resource for investors and traders seeking the latest updates and insights on Sohm stock.
SOHM Inc (SHMN) delivers innovative solutions at the intersection of generic pharmaceuticals and advanced gene editing. This news hub provides investors and industry observers with timely updates on the company’s financial developments, research milestones, and strategic initiatives.
Access authoritative reports on earnings announcements, regulatory filings, and technology advancements like the ABBIE genome editing system. Stay informed about partnerships with leading institutions and progress in CAR-T cell therapy applications.
Our curated collection features press releases detailing manufacturing expansions, cosmeceutical product launches, and biotech collaborations. Discover updates on patent approvals, clinical trial developments, and market expansion strategies.
Bookmark this page for streamlined access to verified information about SHMN’s dual focus areas. Check regularly for new insights into how SOHM Inc navigates the evolving biopharmaceutical landscape through its integrated business model.
SOHM Inc. (OTC PINK:SHMN) has received a Notice of Allowance/Approval from the South Korea Patent Office for its innovative ABBIE gene editing technology. The patent covers the utilization of CAS 9 RETROVIRAL INTEGRASE and CAS 9 RECOMBINASE SYSTEMS for targeted DNA incorporation into cells or organisms.
This milestone expands SOHM's intellectual property portfolio in a key market, supporting licensing opportunities for novel cell therapies, agriculture, and biofuel applications. The company aims to strengthen its position in the global gene editing and cell therapy market, currently valued at $7.96 billion and $4.74 billion respectively in 2023.
The technology is expected to advance the development of new cell therapies for cancer and congenital diseases, while also supporting biofuel development and crop engineering.
SOHM Inc. (OTC PINK:SHMN) has announced significant developments in its biotechnology operations. The company is expanding its ABBIE genome editing and cell engineering program at their Carlsbad facility and UACI labs to support growing Next-Generation Sequencing (NGS) validation requirements.
The strategic expansion aims to meet increasing demands for engineered mouse models and cell lines important for drug development, gene therapy, and immunotherapy. The company is also enhancing its AI-enabled ABBIE platform for next-generation gene editing applications.
Additionally, SOHM will present a poster titled 'ABBIE Gene Editing: A Breakthrough in Precise, Replicable, and Traceable Genomic Integration' at the American Society of Gene and Cell Therapy Conference, scheduled for May 13-17 in New Orleans, LA.
SOHM Inc. (OTC PINK:SHMN) has announced the formation of a dedicated AI team to enhance its ABBIE (A Binding-based Integrase Enzyme) system and develop novel guide RNAs and RNA guided Integrase fusion proteins. The initiative aims to revolutionize genome editing and cell engineering technologies.
The AI team will utilize machine learning algorithms to optimize guide RNAs and Integrase-dCas fusion proteins design, improving the specificity, efficiency, and versatility of genome editing applications. The company plans to develop next-generation genome editing systems and create engineered cells producing custom exosomes with pharmaceutical properties.
According to COO Dr. David Aguilar, these custom exosomes will serve as targeted delivery vehicles for therapeutic agents, with applications in cancer therapy, regenerative medicine, and immunotherapy. The company aims to design exosomes that can efficiently transport drugs, genes, or RNA molecules to specific tissues.
SOHM Inc (OTC PINK:SHMN) has announced significant developments in their ABBIE Technology, revealing a strategic pivot in their business model. The company is transitioning from selling ABBIE kits for independent use to establishing a licensing model, leveraging their global Intellectual Property portfolio.
The company's breakthrough findings indicate that ABBIE technology features unique traceability capabilities absent in competing technologies, potentially streamlining FDA approval processes and enhancing therapy safety. SOHM is currently in technical diligence discussions with both small innovators and major pharmaceutical companies, focusing on applications in CAR-T therapy, cancer drug development, and gene therapy.
The company plans to publish these findings in Q2 2025 and will organize platform seminars to showcase the technology's potential in revolutionizing cancer treatment.
SOHM Inc. (OTC PINK:SHMN) has appointed Dr. Wei Zhu as Senior Marketing and Sales Consultant for its biotech ABBIE division. Dr. Zhu brings over 20 years of experience in Molecular and Cellular Biology, Biochemistry, Immunology, Signal Transduction, Cancer Biology, and Developmental Biology. Her expertise includes advanced Bioinformatics, Sequence-based Genomics Research, Histology, and animal model work. The appointment is effective immediately, and she will contribute to the company's marketing and sales efforts in pharmaceutical, cosmeceutical, and nutraceutical products.
SOHM Inc (OTC PINK:SHMN) has received a patent allowance from Japan's Patent Office for its ABBIE Genome Editing technology. The patent (No. 2023-121860) protects SOHM's innovative SAGE (SOHM-ABBIE Genome Editing) products and services, which enable precise DNA alterations without causing double-stranded breaks. This technology advancement positions SOHM competitively in the global Cell Therapy market, valued at $4.5 Billion in 2023 and projected to reach $97 Billion by 2033. The company plans to expand its presence in Japan, Korea, China, EU, and other global markets through product sales, services, and strategic partnerships.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has appointed Dr. David Zarling as its Senior Product Development Advisor. Dr. Zarling brings extensive experience in biotechnology, pharmaceuticals, and nutraceuticals, having served in advisory roles at SRI International-BioSciences Division, Pangene , and Colby Pharmaceutical Company. His expertise spans product development, strategic partnering, and innovation in biologic and pharma drug solutions.
Dr. Zarling's background includes work in oncology, immunology, inflammation, infectious and neurodegenerative diseases. His appointment is expected to contribute to SOHM's product development, marketing, and sales efforts, including the company's ABBIE technology products. CEO Baron Night expressed confidence that this addition will help achieve higher revenue growth in 2024 compared to previous years.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has filed a new provisional patent application with the USPTO. The application, titled 'DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING', describes specific combinations of guide RNAs used with the ABBIE system to increase targeting and efficiency.
This development comes ten months after SOHM's announcement of their 'SMART' gene editing provisional application. The company aims to expand its patent portfolio in the cell engineering space, with the goal of becoming a significant player and leader in gene editing technology and products.
Dr. David Aguilar, COO of SOHM, expressed satisfaction with the progress in developing the ABBIE system and its potential, stating that these technical advances provide the competitive edge needed in this highly contested field.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced receiving pre-launch orders for their ABBIE Technology kits. This marks a significant milestone as the company transitions from R&D to commercialization of GLP ABBIE Technology Kits. The CRISPR/Cas9 kits market is projected to reach $17.4 billion by 2032.
SOHM's ABBIE technology offers faster and more efficient integration of genetic sequences into cell DNA compared to traditional methods, reducing time and costs. The company's data shows that ABBIE expressing mRNA with guide RNAs integrates donor DNA more efficiently than without guide RNAs.
Management is confident that these pre-launch orders will open new opportunities for their technology. They plan to share updates on collaborations, including one with Stanford Medicine. SOHM aims for higher revenue growth in 2024, partly driven by the new ABBIE kits.
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced the appointment of Dr. Tetsuya Kawamura, Ph.D., as a Senior Cell Engineer and Biochemist. Dr. Kawamura brings extensive experience in biochemistry, molecular biology, and cellular biology. He has a proven track record in developing new methods for cell model creation, protein expression, and DNA/RNA production. Notably, Dr. Kawamura has authored patents in gene editing technology, including SOHM's ABBIE technology.
Dr. Kawamura's appointment is expected to enhance SOHM's scientific capabilities and support the advancement and commercialization of their ABBIE gene editing technology. The company anticipates that his expertise will aid in the timely release of ABBIE kits, as previously announced for the current quarter.
